Drug Delivery Device Market Size to Exceed USD 419.14 Bn by 2032

The Drug Delivery Device Market, estimated at USD 229.14 Bn in 2025, is expected to exhibit a CAGR of 9% and reach USD 419.14 Bn by 2032.

The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.

Market Dynamics:

Global drug delivery device market growth is primarily driven by  increasing prevalence of chronic diseases worldwide. According to the World Health Organization (WHO), chronic diseases accounted for approximately 70% of all deaths globally in 2020. Growing geriatric population who are more prone to developing chronic conditions  can also boost demand for drug delivery devices  in the future.  Technological innovations  allows development of novel drug delivery devices with enhanced convenience, efficacy and safety. For instance, wearable drug delivery devices and microchip implants  can achieve improved treatment outcomes among patients. The advent of such innovative and user-friendly devices  can boost the adoption of drug delivery systems during the forecast period.

Growing prevalence of chronic diseases can boost demand for drug delivery devices

 Rising prevalence of chronic diseases such as diabetes, cancer and cardiovascular diseases across the globe can drive the global drug delivery device market growth. These chronic conditions require regular medication and treatment over long periods  that boosts demand for drug delivery devices that allow for pain-free and accurate delivery of drugs. According to the WHO, cardiovascular diseases are the number one cause of death globally and are a leading cause of disability and healthcare expenditure. Managing chronic conditions safely and effectively through drug delivery devices helps improve patient outcomes and quality of life.

Increasing biologics usage boosts new product developments

 Rising usage of biologics and large molecule drugs can boost innovations in drug delivery devices. Biologics are often injectable and unstable drugs that require special devices and formulations for effective delivery. Their large size and complexity poses challenges in development of delivery methods. With growing research into monoclonal antibodies, peptides and vaccines, companies are investing heavily in the design of advanced devices like injectors, auto-injectors and pumps that can stably deliver biologics. Rising demand for simple-to-use, prefilled and wearable devices  encourages continuous product line extensions and upgrades.

Regulatory hurdles pose compliance challenges

Stringent regulatory pathways for approval of combination drugs and delivery devices can hamper the market growth. Regulations vary across geographies and navigating different guidelines delays market access. Obtaining the necessary licenses and meeting all quality and safety standards involves high costs. It also increases the number of clinical trials required to prove the combined safety and efficacy of the drug-device product. Non-compliance with evolving regulations can attract penalties, recalls or market withdrawal.  Maintaining transparency with regulators throughout product development remains crucial.

Reimbursement policies impact adoption rates

Reimbursement policies regarding drug delivery devices can influence their adoption rates. Full or partial coverage under insurance and reimbursement programs is essential for patients to afford advanced devices. However, coverage approval can take time and differ between private payers and public programs. It remains unclear if certain innovative drug-device combinations will be covered or reimbursement rates will support their prices. This payment uncertainty adds to the financial risks, especially for emerging startups focusing on niche delivery technologies. Close coordination with payers is needed to ensure smooth access and adoption.

Untapped emerging markets present lucrative opportunities

Emerging economies in Asia Pacific, Latin America, Africa and the Middle East currently account for a small share of the global drug delivery device market but will offer huge untapped growth opportunities near future. Rising incomes, growing unmet medical needs, increasing access to healthcare and expanding public and private insurances can boost demand these underpenetrated regions. Companies that invest in developing low-cost products adapted for resource-limited settings and invest in promotional activities can gain significant markets shares. Partnering with local players also helps establish reliable supply chains and distribution networks.

Increasing adoption of self-administration and home care trends

Growing popularity of self-administered and home care treatment options using drug delivery devices can offer growth opportunity. Patient preferences are strongly inclined towards self-injectable devices and wearable pumps that offer freedom and flexibility instead of relying on healthcare facility visits. Home infusion therapies help avoid hospital stays and lower healthcare costs. Device miniaturization, integration of connectivity into devices and availability of training resources are enabling more chronic conditions to be safely managed at home. This trend is catalyzing innovative solutions that enhance patient adherence, comfort and treatment outcomes.

Key Developments:

• In April 2024, Bespak completed its spin-out from Recipharm, forming a new standalone company specializing in drug-device combination products and drug delivery devices for pulmonary and nasal inhalation. CEO Chris Hirst stated that the new Bespak aims to be a trusted innovation partnernd sustainability leader in the shift towards greener inhalers.
• In November 2023, Hovione, a leading CDMO in spray drying and particle engineering, expanded its nasal drug delivery capabilities by introducing a new range of innovative nasal powder delivery devices developed in partnership with IDC. Intranasal delivery offers a simple, safe, and fast-acting alternative to conventional routes, with growing potential for delivering drugs to the brain for treating central nervous system (CNS) diseases.
• In June 2022, Gufic Biosciences Ltd introduced a new drug delivery system, Dual Chamber Bags, at affordable prices for the first time in India
• In February 2022, Takeda received the U.S. FDA approval for TAKHZYRO (lanadelumab-flyo) injection in a single-dose prefilled syringe (PFS). It is designed to prevent hereditary angioedema (HAE) attacks in adult and pediatric patients aged 12 years and older.

Link: https://www.coherentmarketinsights.com/market-insight/drug-delivery-device-market-5419

Key Players:

Abbott Laboratories, Adherium Ltd., Amiko Digital Health Limited, Becton, Dickinson and Company, BIOCORP, CeQur Corporation, Cognita Labs, E3D Elcam Drug Delivery Devices, H&T Presspart Manufacturing Ltd., HCmed Innovations Co., Ltd., Medtronic plc, Novo Nordisk A/S, Phillips-Medisize, Sonceboz, Enable Injections, Inc., NOVO Engineering, Elcam Medical, Battelle, Gerresheimer AG, Aphios